<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936832</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000637832</org_study_id>
    <secondary_id>FFCD-0801</secondary_id>
    <secondary_id>EUDRACT-2008-005959-19</secondary_id>
    <secondary_id>EU-20918</secondary_id>
    <nct_id>NCT00936832</nct_id>
  </id_info>
  <brief_title>Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>Front-line Combination Therapy of Sunitinib Malate Plus Chemotherapy With Leucovorin/5-Fluorouracil and Irinotecan (FOLFIRI) for Rectal Cancer Patients With Synchronous Non-Resectable Metastases: A Phase II Non Controlled Study. (SUREMETS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in&#xD;
      chemotherapy, such as irinotecan hydrochloride, leucovorin calcium, and fluorouracil, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving more than one drug (combination chemotherapy) together with&#xD;
      sunitinib malate may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving sunitinib malate together with&#xD;
      combination chemotherapy works as front-line therapy in treating patients with metastatic&#xD;
      rectal cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluation of the efficacy of front-line treatment with sunitinib malate and FOLFIRI&#xD;
           chemotherapy at 3 months in patients with rectal cancer and synchronous metastases&#xD;
           deemed unresectable in a multidisciplinary consultation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the rate of resection of secondary metastases and rectal cancer, rate of R0&#xD;
           resection of metastases and rectal cancer, and the rate of complete response after&#xD;
           resection.&#xD;
&#xD;
        -  Evaluate the rate of local failure (progression of rectal cancer).&#xD;
&#xD;
        -  Evaluate the rate of local complications.&#xD;
&#xD;
        -  Evaluate disease-free survival.&#xD;
&#xD;
        -  Evaluate progression-free survival, metastatic progression-free survival, and local&#xD;
           progression-free survival.&#xD;
&#xD;
        -  Evaluate symptom-free survival.&#xD;
&#xD;
        -  Evaluate overall survival.&#xD;
&#xD;
        -  Evaluate quality of life, specifically fatigue and global health score (EORTC QLQ-C30).&#xD;
&#xD;
        -  Evaluate the tolerance to treatment.&#xD;
&#xD;
        -  Conduct translational research, in particular, pharmacokinetic studies of plasma and&#xD;
           rectal tumor biopsies, and histological and molecular studies.&#xD;
&#xD;
      OUTLINE: Patients receive simplified FOLFIRI chemotherapy comprising irinotecan hydrochloride&#xD;
      IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on&#xD;
      days 1, 15, and 29. Patients also receive oral sunitinib malate once daily on days 1-28.&#xD;
      Treatment repeats every 6 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients may undergo surgical resection and/or local radiotherapy if the tumor regresses.&#xD;
      After resection or radiotherapy, patients may undergo up to 4 more courses of study&#xD;
      treatment.&#xD;
&#xD;
      Biopsies of the tumor and healthy mucosa are collected for translational research at&#xD;
      baseline. Blood samples are collected for pharmacodynamic and pharmacogenetic studies at&#xD;
      baseline and at week 6. Patients also complete a quality-of-life questionnaire (EORTC&#xD;
      QLQ-C30) at baseline and periodically thereafter.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    because the sunitinib showed futility in anotehr trial&#xD;
  </why_stopped>
  <start_date>April 2009</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate at 3 months as assessed by RECIST criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complete response after resection</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of R0 resection of metastases</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of local failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of local complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastatic progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life, specifically fatigue and global health score (EORTC QLQ-C30)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration of the final score for overall health and fatigue</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance and incidence of side effects as assessed by NCI CTCAE v2</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational research including pharmacodynamic studies of plasma and rectal tumor biopsies and histological and molecular studies</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the rectum&#xD;
&#xD;
               -  Lower pole of the tumor &lt; 12 cm from the anal margin&#xD;
&#xD;
          -  Synchronous metastases of the liver and/or lung&#xD;
&#xD;
               -  Unresectable or resectability uncertain according to the decision of a local&#xD;
                  multidisciplinary consultation&#xD;
&#xD;
          -  Lesions measurable in 1 dimension by RECIST criteria (metastases and primary rectal&#xD;
             cancer)&#xD;
&#xD;
          -  No rectal obstruction requiring surgery or the emergency fitting of a prosthesis&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL (transfusions allowed)&#xD;
&#xD;
          -  FEV ≥ 50%&#xD;
&#xD;
          -  QT interval ≤ 450 ms (in men) or ≤ 470 ms (in women)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  Serum albumin ≥ 25 g/L&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of another cancer except for nonmelanoma skin cancer or curatively treated&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
               -  History of other cancers allowed provided the patient has been disease-free &gt; 3&#xD;
                  years&#xD;
&#xD;
          -  None of the following:&#xD;
&#xD;
               -  Congestive heart failure or coronary heart disease&#xD;
&#xD;
               -  Myocardial infarction within the past year&#xD;
&#xD;
               -  Uncontrolled hypertension (systolic BP &gt; 160 mm Hg or diastolic BP &gt; 100 mm Hg)&#xD;
                  despite optimal medical management&#xD;
&#xD;
          -  No active severe rectal bleeding&#xD;
&#xD;
          -  No liver failure&#xD;
&#xD;
          -  No known Gilbert syndrome&#xD;
&#xD;
          -  No severe uncontrolled infection&#xD;
&#xD;
          -  No chronic diarrhea, malabsorption syndrome, or intestinal obstruction/subocclusion&#xD;
&#xD;
          -  No severe uncontrolled pain (visual analogue scale 5/10) with morphine treatment&#xD;
&#xD;
          -  No other medical, psychological, or social condition that, in the investigator's&#xD;
             opinion, could affect the patient's compliance with study treatment&#xD;
&#xD;
          -  No hypersensitivity to any component of study treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Patient Characteristics&#xD;
&#xD;
          -  No prior radiotherapy to the pelvis&#xD;
&#xD;
          -  More than 4 weeks since prior experimental therapy&#xD;
&#xD;
          -  More than 7 days since prior CYP3A4 inhibitor before the administration of sunitinib&#xD;
             malate&#xD;
&#xD;
          -  More than 12 days since prior CYP3A4 inducer&#xD;
&#xD;
          -  No concurrent participation in another clinical study&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Rougier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Ambroise Pare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Ambroise Pare</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>liver metastases</keyword>
  <keyword>lung metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

